Retrospective Study on the Efficacy and Safety of Dulaglutide in Patients with Diabetes and Moderate-Advanced Chronic Kidney Disease

Sriya Kosaraju1 Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA

Rong M Zhang2 Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence[email protected]
View further author information

References

Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney Dial. 2022;2(3):433–442. doi:10.3390/kidneydial2030038
Google Scholar
Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–617. doi:10.1016/S2213-8587(18)30104-9
PubMed Web of Science ®Google Scholar
Rossing P, Caramori ML, Chan JC, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1–S127.
PubMedGoogle Scholar
Kim S, An JN, Song YR, et al. Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease. PLoS One. 2022;17(8):e0273004. doi:10.1371/journal.pone.0273004
PubMed Web of Science ®Google Scholar
Chen J, Wu C, Jenq C, et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. JAMA Network Open. 2022;5(3):e221169. doi:10.1001/jamanetworkopen.2022.1169
PubMed Web of Science ®Google Scholar